CYP2J2 Double Nickase Plasmid (h): sc-402955-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CYP2J2 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- CYP2J2 Double Nickase Plasmid (h) and CYP2J2 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting CYP2J2. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CYP2J2 Antibody (D-6): sc-137127
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CYP2J2 Double Nickase Plasmid (h) | sc-402955-NIC | 20 µg | $410.00 | |||
CYP2J2 Double Nickase Plasmid (h2) | sc-402955-NIC-2 | 20 µg | $410.00 |
CYP2J2 encodes a human cytochrome P450 epoxygenase that oxidizes endogenous lipids, including conversion of arachidonic acid to epoxyeicosatrienoic acids (EETs), bioactive mediators that influence vascular tone, inflammatory signaling, and cellular stress responses. Through microsomal monooxygenase activity, CYP2J2 intersects with eicosanoid metabolism and redox homeostasis pathways that can modulate endothelial function and smooth muscle biology. Altered CYP2J2 expression or activity has been studied in the context of cardiometabolic traits, inflammatory states, and tumor cell phenotypes, reflecting its role in lipid mediator balance and cellular signaling. As a xenobiotic-metabolizing enzyme, CYP2J2 also contributes to oxidative biotransformation of select compounds, making it relevant for pharmacology and toxicology research.
CYP2J2 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the CYP2J2 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within CYP2J2. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt CYP2J2 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of CYP2J2-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.